Landos Biopharma, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-06-01
- Employees
- 19
- Market Cap
- -
Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis
Phase 1
Completed
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: NX-13 250mg IRDrug: NX-13 500mg IRDrug: NX-13 500mg MRDrug: Placebo
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Landos Biopharma Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT04862741
- Locations
- 🇺🇸
Allameh Medical Corporation, Mission Viejo, California, United States
🇺🇸Avant Research Associates, LLC, Austin, Texas, United States
🇺🇦Communal Enterprise I.I.Mechnykov Dnipropetrovsk Regional Clinical Hospital of Dnipropetrovsk Regional Counsil, cont., Dnipro, Ukraine
Safety, Tolerability and Pharmacokinetics of Oral NX-13 in Healthy Adults Male and Female Volunteers
Phase 1
Completed
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: NX-13 250 mgDrug: Placebo
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Landos Biopharma Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT04458805
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Australia
© Copyright 2025. All Rights Reserved by MedPath